CTOs on the Move

MyoKardia

www.myokardia.com

 
Our Mission: Change the world for patients with cardiovascular disease through bold and innovative science. MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus: treatment of heritable cardiomyopathies, a group of genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We are a growing community of employees who enjoy working with and learning from each other. We collaborate in a way that ensures the growth of the company as well each employee ...
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.myokardia.com
  • 333 Allerton Avenue
    South San Francisco, CA USA 94080
  • Phone: 650.741.0900

Executives

Name Title Contact Details

Funding

MyoKardia raised $46M on 05/01/2015

Similar Companies

Epirium Bio

Epirium Bio is a clinical-stage biopharmaceutical company developing therapeutics that promote mitochondrial biogenesis and function through a novel mechanism of action discovered by the company.

Hummingbird Bioscience

Precision Medicine. Precision Therapies.Hummingbird Bioscience is leading a bold new way of engineering precision biotherapeutics that can define the future of precision medicine. We focus on important biologically validated targets in cancer and autoi...

Vesigen Therapeutics

Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology.

Powerpollen

PowerPollen offers a breakthrough, scalable technology to collect, preserve and apply pollen on-demand to help improve the productivity, profitability and sustainability of modern farming practices.

Cybrexa

Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. Early clinical trials of the company`s lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer. As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology.